Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Panbela Therapeutics Inc (PBLA)
Panbela Therapeutics Inc (PBLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,845
  • Shares Outstanding, K 2,958
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,930 K
  • 60-Month Beta 1.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.68
Trade PBLA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -2.06
  • Number of Estimates 2
  • High Estimate -1.83
  • Low Estimate -2.29
  • Prior Year -252.25
  • Growth Rate Est. (year over year) +99.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2100 +5.79%
on 09/25/23
1.5400 -16.88%
on 09/05/23
-0.0500 (-3.76%)
since 08/28/23
3-Month
1.2100 +5.79%
on 09/25/23
3.0700 -58.31%
on 07/19/23
-0.9400 (-42.34%)
since 06/28/23
52-Week
1.2100 +5.79%
on 09/25/23
444.0000 -99.71%
on 09/29/22
-428.3200 (-99.70%)
since 09/28/22

Most Recent Stories

More News
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

CRSP : 45.74 (-2.95%)
KALA : 8.83 (-1.45%)
ALLO : 3.41 (+0.59%)
PBLA : 1.2800 (-1.54%)
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP

Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.

CRSP : 45.74 (-2.95%)
KALA : 8.83 (-1.45%)
ALLO : 3.41 (+0.59%)
PBLA : 1.2800 (-1.54%)
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Expects interim data by early 2024...

PBLA : 1.2800 (-1.54%)
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 1.2800 (-1.54%)
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 1.2800 (-1.54%)
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction,...

PBLA : 1.2800 (-1.54%)
Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 1.2800 (-1.54%)
Panbela Announces Poster Presentation at American Association for Cancer Research:

The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer...

PBLA : 1.2800 (-1.54%)
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to...

PBLA : 1.2800 (-1.54%)
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

PBLA : 1.2800 (-1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma,...

See More

Key Turning Points

3rd Resistance Point 1.3500
2nd Resistance Point 1.3400
1st Resistance Point 1.3200
Last Price 1.2800
1st Support Level 1.2900
2nd Support Level 1.2800
3rd Support Level 1.2600

See More

52-Week High 444.0000
Fibonacci 61.8% 274.8542
Fibonacci 50% 222.6050
Fibonacci 38.2% 170.3558
Last Price 1.2800
52-Week Low 1.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar